Zimmer Biomet has achieved a perfect 4-for-4 earnings beat streak and a maximum Piotroski F-Score of 9/9, yet trades at a death-cross technical setup with almost no gap to its analyst price target, making the risk-reward unattractive at current levels.
Thesis pillars
- Perfect Earnings Beat Streak↑Improving
- Maximum Piotroski Quality Score→Stable
- Analyst Target Exhausted↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 20, 2026
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $96.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source materials and components; Analyst target reached - limited upside remaining.
Zimmer Biomet designs, manufactures and markets orthopedic implants (knees, hips), sports medicine/biologics/trauma products, craniomaxillofacial devices, and digital/robotic technologies across Americas, EMEA and Asia Pacific segments. Approximately 85% of 2025 net sales were... Read more
Hold if already holding. Not a fresh buy at $96.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source materials and components; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.1/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Recent developments
updated 2026-10-29Recent Developments — Zimmer Biomet Holdings, Inc.
Latest news
- NEWS Zimmer Biomet (ZBH) Is Up 7.7% After Q1 Beat And Confident Outlook Commentary - What's Changed - finance.yahoo.com — finance.yahoo.com positive
- NEWS Zimmer Biomet (ZBH) Is Up 7.7% After Q1 Beat And Confident Outlook Commentary - What's Changed - Yahoo Finance — Yahoo Finance positive
- NEWS Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? - TradingView — TradingView neutral
- NEWS Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? - finance.yahoo.com — finance.yahoo.com neutral
- NEWS Zimmer Biomet Set to Report Q2 Earnings: What's in the Cards? - tradingview.com — tradingview.com neutral
Generated 2026-10-29T11:14:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSuppliersingle-source materials and components10-K Item 1A: 'Certain of these materials and components and outsourced activities can only be obtained from a single source or a limited number of sources due to quality considerations'
Material Events(8-K, last 90d)
- 2026-04-28Item 5.02MEDIUMCFO Suketu Upadhyay resigned effective April 28, 2026 to pursue a new professional opportunity; no disagreement with the company cited. Paul Stellato (VP, Controller and CAO) appointed interim CFO; permanent search underway.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $96.39, but acceptable to hold if already in. Reasons: Concentration risk — Supplier: single-source materials and components; Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $96.21 reached (−0.2%), stop $91.67 (−5.1%), A.R:R -0.0:1. Score 6.1/10, moderate confidence.
Analyst target $96.21 reached (−0.2% from $96.39); no take-profit level is published. Analyst target $96.21 reached (−0.2%), stop $91.67 (−5.1%), A.R:R -0.0:1. Stop-loss: $91.67.
Concentration risk — Supplier: single-source materials and components; Analyst target reached - limited upside remaining; Earnings in 6 days (event risk).
Zimmer Biomet Holdings, Inc. trades at a P/E of 23.4 (forward 10.6). TrendMatrix value score: 7.2/10. Verdict: Hold.
32 analysts cover ZBH with a consensus score of 3.4/5. Average price target: $107.
What does Zimmer Biomet Holdings, Inc. do?Zimmer Biomet designs, manufactures and markets orthopedic implants (knees, hips), sports medicine/biologics/trauma...
Zimmer Biomet designs, manufactures and markets orthopedic implants (knees, hips), sports medicine/biologics/trauma products, craniomaxillofacial devices, and digital/robotic technologies across Americas, EMEA and Asia Pacific segments. Approximately 85% of 2025 net sales were consignment-based; no single customer exceeded 2% of net sales. The company employed approximately 17,000 people worldwide as of December 31, 2025.